Company news

Eupraxia Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

October 31, 2024

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

October 28, 2024

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

October 15, 2024

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

October 10, 2024

Eupraxia Pharmaceuticals Strengthens Senior Management Team

October 2, 2024

Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

September 11, 2024

Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 4, 2024

Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results

August 7, 2024

Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility

August 2, 2024

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo

July 8, 2024

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024

July 3, 2024

Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024

June 5, 2024

Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

May 23, 2024

Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024

May 22, 2024

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

May 21, 2024

Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024

May 14, 2024

Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024

Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board

May 2, 2024

Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

April 11, 2024

Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference

April 8, 2024

Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today

April 5, 2024

Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024

April 3, 2024

Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results

April 1, 2024

Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

February 5, 2024

Eupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IAR

February 1, 2024

Eupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the Knee

January 30, 2024

Eupraxia Pharmaceuticals Announces Filing of Preliminary MJDS Base Shelf Prospectus

January 8, 2024

Eupraxia Pharmaceuticals Announces Positive Clinical Data in EP-104GI RESOLVE Trial

December 12, 2023

Eupraxia Pharmaceuticals Announces Clinical and Corporate Update

December 11, 2023

Eupraxia Pharmaceuticals Reports Third Quarter 2023 Financial Results

November 14, 2023

Eupraxia Pharmaceuticals to Present at the 2023 Annual Meeting of the American College of Rheumatology

November 1, 2023

Eupraxia Pharmaceuticals Announces Initiation of Second Cohort in Phase 1b/2a Clinical Trial in Eosinophilic Esophagitis

October 11, 2023

Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 11, 2023

Eupraxia Pharmaceuticals Announces Change of Auditor

September 7, 2023

Eupraxia Pharmaceuticals Announces Presentation at PAINWeek 2023

September 6, 2023

Eupraxia Pharmaceuticals Announces Closing of Non-Brokered Private Placement for Gross Proceeds of C$22,287,125

August 18, 2023

Eupraxia Pharmaceuticals Reports Second Quarter 2023 Financial Results

August 11, 2023

Eupraxia Pharmaceuticals Announces a Non-Brokered Private Placement of up to C$22 Million

August 4, 2023

Eupraxia Pharmaceuticals Reports Positive Topline Data in its Phase 2b Osteoarthritis Trial with EP-104IAR

June 26, 2023

Eupraxia Pharmaceuticals Announces Filing of Preliminary Base Shelf Prospectus

June 15, 2023

Eupraxia Pharmaceuticals Receives U.S. FDA Fast Track Designation for EP-104IAR in Treatment of Osteoarthritis

June 13, 2023

Eupraxia Pharmaceuticals Doses First Patient in Phase 1b/2a Eosinophilic Esophagitis Trial

June 8, 2023

Eupraxia Pharmaceuticals Announces Last Patient Last Visit in Phase 2 Osteoarthritis Clinical Trial of EP-104IAR

May 25, 2023

Eupraxia Pharmaceuticals Announces Appointment of Dr. Mark Kowalski as Chief Medical Officer

May 18, 2023

Eupraxia Pharmaceuticals Reports First Quarter 2023 Financial Results

May 11, 2023

Eupraxia Pharmaceuticals Reports Fourth Quarter and 2022 Financial Results

March 23, 2023

Eupraxia Pharmaceuticals Completes Patient Enrollment for its Phase 2 Trial in Knee Osteoarthritis

December 7, 2022

Eupraxia Pharmaceuticals Reports Third Quarter 2022 Financial Results

November 7, 2022

Eupraxia Pharmaceuticals Appoints Chief Business Officer

November 1, 2022

Eupraxia Pharmaceuticals Initiates Phase 2 Study in Eosinophilic Esophagitis

October 12, 2022

← Newer news releases · Older news releases →

Decks